These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32535904)

  • 1. Short-term anticoagulation after acute cardioversion of early-onset atrial fibrillation.
    Saglietto A; De Ferrari GM; Gaita F; Anselmino M
    Eur J Clin Invest; 2020 Nov; 50(11):e13316. PubMed ID: 32535904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial fibrillation patients with CHA2DS2-VASc >1 benefit from oral anticoagulation prior to cardioversion.
    Själander S; Svensson PJ; Friberg L
    Int J Cardiol; 2016 Jul; 215():360-3. PubMed ID: 27128562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation.
    Femia G; Fetahovic T; Shetty P; Lee A
    Heart Lung Circ; 2018 Jul; 27(7):798-803. PubMed ID: 28802808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboembolic events following cardioversion of acute atrial fibrillation and flutter: a systematic review and meta-analysis.
    Wong BM; Perry JJ; Cheng W; Zheng B; Guo K; Taljaard M; Skanes AC; Stiell IG
    CJEM; 2021 Jul; 23(4):500-511. PubMed ID: 33715143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion.
    Itäinen S; Lehto M; Vasankari T; Mustonen P; Kotamäki M; Numminen A; Lahtela H; Bah A; Hartikainen J; Hekkala AM; Airaksinen JKE
    Europace; 2018 Apr; 20(4):565-568. PubMed ID: 29016758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
    Klein HH
    Dtsch Med Wochenschr; 2013 Jun; 138(24):1309-11. PubMed ID: 23737116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
    Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke and thromboembolism prevention in atrial fibrillation.
    Jame S; Barnes G
    Heart; 2020 Jan; 106(1):10-17. PubMed ID: 31533990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to oral anticoagulant treatment and risk factor assessment six months after DC-conversion of atrial fibrillation.
    Kjekshus VHR; Schuster P
    Scand Cardiovasc J; 2020 Jun; 54(3):179-185. PubMed ID: 31913722
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardioversion for atrial fibrillation - how to prevent thromboembolic complications?
    Jaakkola S; Kiviniemi TO; Airaksinen KEJ
    Ann Med; 2018 Nov; 50(7):549-555. PubMed ID: 30207497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study.
    Airaksinen KE; Grönberg T; Nuotio I; Nikkinen M; Ylitalo A; Biancari F; Hartikainen JE
    J Am Coll Cardiol; 2013 Sep; 62(13):1187-92. PubMed ID: 23850908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study).
    Sorino M; Colonna P; De Luca L; Carerj S; Oliva E; De Tommasi SM; Conti U; Iacopi F; D'Agostino C; D'Amato N; Pettinati G; Montericcio V; Cualbu A; De Luca I
    J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1034-42. PubMed ID: 18163016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anticoagulation in cardioversion of atrial fibrillation. Current status and outlook for the future].
    Schimpf T; Stellbrink C
    Med Klin (Munich); 2003 Feb; 98(2):91-5. PubMed ID: 12601533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin.
    Frederiksen AS; Albertsen AE; Christesen AMS; Vinter N; Frost L; Møller DS
    Europace; 2018 Jul; 20(7):1078-1085. PubMed ID: 28655151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk.
    Tampieri A; Cipriano V; Mucci F; Rusconi AM; Lenzi T; Cenni P
    Intern Emerg Med; 2018 Jan; 13(1):87-93. PubMed ID: 28025766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.
    Zhu WG; Xiong QM; Hong K
    Tex Heart Inst J; 2015 Feb; 42(1):6-15. PubMed ID: 25873792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.
    Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J
    Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation in atrial fibrillation: a contemporary viewpoint.
    Wyse DG
    Heart Rhythm; 2007 Mar; 4(3 Suppl):S34-9. PubMed ID: 17336882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.